Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Stomach Neoplasms 6Pancreatic Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Carcinoma, Hepatocellular 5Esophageal Squamous Cell Carcinoma 4Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Gastrointestinal Neoplasms 3Esophageal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Breast Neoplasms 2Biliary Tract Neoplasms 2Adenocarcinoma 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neutropenia 1Neuroendocrine Tumors 1Neoplasm Recurrence, Local 1Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum 1Mouth Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Lung Neoplasms 1Laryngeal Neoplasms 1

Interventions

Trastuzumab 1Oxaliplatin 1Fluorouracil 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × HER2-positive Gastric Cancer × Fluorouracil × Clear all
NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡